Zacks: Analysts Set $6.50 Target Price for Edap Tms SA (NASDAQ:EDAP)

Shares of Edap Tms SA (NASDAQ:EDAP) have received a consensus broker rating score of 1.00 (Strong Buy) from the one brokers that provide coverage for the company, Zacks Investment Research reports. One equities research analyst has rated the stock with a strong buy recommendation.

Brokers have set a twelve-month consensus price objective of $6.50 for the company and are forecasting that the company will post $0.01 EPS for the current quarter, according to Zacks. Zacks has also assigned Edap Tms an industry rank of 76 out of 256 based on the ratings given to related companies.

A number of equities analysts recently weighed in on the stock. HC Wainwright set a $7.00 price objective on shares of Edap Tms and gave the stock a “buy” rating in a report on Tuesday, June 11th. ValuEngine lowered shares of Edap Tms from a “buy” rating to a “hold” rating in a research note on Thursday, August 1st. TheStreet lowered shares of Edap Tms from a “b-” rating to a “d+” rating in a research note on Monday, June 17th. Finally, Zacks Investment Research upgraded shares of Edap Tms from a “sell” rating to a “hold” rating in a research note on Tuesday, July 16th.

Edap Tms stock traded up $0.12 during midday trading on Tuesday, hitting $3.12. The company’s stock had a trading volume of 202,900 shares, compared to its average volume of 189,329. The company has a debt-to-equity ratio of 0.09, a current ratio of 2.40 and a quick ratio of 1.97. The business’s 50-day simple moving average is $2.79. Edap Tms has a 12 month low of $1.35 and a 12 month high of $5.42. The firm has a market capitalization of $85.26 million, a P/E ratio of 156.00 and a beta of 1.76.

Edap Tms (NASDAQ:EDAP) last posted its quarterly earnings data on Wednesday, May 15th. The medical equipment provider reported $0.01 earnings per share for the quarter, meeting the Thomson Reuters’ consensus estimate of $0.01. Edap Tms had a negative return on equity of 1.13% and a negative net margin of 0.36%. The business had revenue of $11.50 million for the quarter, compared to analysts’ expectations of $13.25 million. As a group, equities analysts predict that Edap Tms will post 0.08 EPS for the current fiscal year.

An institutional investor recently raised its position in Edap Tms stock. Fosun International Ltd lifted its stake in Edap Tms SA (NASDAQ:EDAP) by 45.9% in the 1st quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 363,485 shares of the medical equipment provider’s stock after purchasing an additional 114,342 shares during the period. Fosun International Ltd owned 1.25% of Edap Tms worth $1,072,000 at the end of the most recent reporting period. Institutional investors and hedge funds own 10.32% of the company’s stock.

Edap Tms Company Profile

EDAP TMS SA, together with its subsidiaries, develops, produces, markets, distributes, and maintains a portfolio of minimally-invasive medical devices for the treatment of urological diseases worldwide. The company operates in two divisions: High Intensity Focused Ultrasound (HIFU), and Urology Devices and Services (UDS).

Featured Article: Why investors pay attention to retained earnings

Get a free copy of the Zacks research report on Edap Tms (EDAP)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Edap Tms Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Edap Tms and related companies with MarketBeat.com's FREE daily email newsletter.